OncoMatch/Clinical Trials/NCT06007924
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Official title: Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients
Is NCT06007924 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Avutometinib and Defactinib for thyroid cancer.
Treatment: Avutometinib · Defactinib — The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects. Funding Source- FDA OOPD.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Thyroid Gland Carcinoma
Biomarker criteria
Required: KRAS mutation
RAS mutation
Required: NRAS mutation
RAS mutation
Required: HRAS mutation
RAS mutation
Required: NF1 mutation
NF1 mutation
Required: RET rearrangement
RET rearrangement
Required: NTRK1 rearrangement
NTRK rearrangement
Required: NTRK2 rearrangement
NTRK rearrangement
Required: NTRK3 rearrangement
NTRK rearrangement
Required: ALK rearrangement
ALK rearrangement
Required: BRAF class 2 or 3 mutation (non-v600e/k) or rearrangement
Class 2 or 3 BRAF alterations (non-V600E/K mutations or rearrangements)
Required: BRAF v600e
anaplastic thyroid cancer harboring a Class 1 BRAF alteration (V600E/K/D/R) also would be eligible if the patient has previously been treated with BRAF-targeted therapy
Required: BRAF v600k
anaplastic thyroid cancer harboring a Class 1 BRAF alteration (V600E/K/D/R) also would be eligible if the patient has previously been treated with BRAF-targeted therapy
Required: BRAF v600d
anaplastic thyroid cancer harboring a Class 1 BRAF alteration (V600E/K/D/R) also would be eligible if the patient has previously been treated with BRAF-targeted therapy
Required: BRAF v600r
anaplastic thyroid cancer harboring a Class 1 BRAF alteration (V600E/K/D/R) also would be eligible if the patient has previously been treated with BRAF-targeted therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MEK 1/2 inhibitor
Exception: patients who received these therapies for a defined period of time to enhance radioiodine activity or as part of treatment for BRAF V600E/K/D/R mutant anaplastic thyroid cancer
Prior therapy with a MEK 1/2 inhibitor
Cannot have received: inhibitor that targets Class II/Class III BRAF alterations
Exception: patients who received these therapies for a defined period of time to enhance radioiodine activity
inhibitor that targets Class II/Class III BRAF alterations
Cannot have received: FAK inhibitor
Exception: patients who received these therapies for a defined period of time to enhance radioiodine activity
FAK inhibitor
Lab requirements
Blood counts
WBC ≥ 2000/μL; Neutrophils ≥ 1000/μL; Platelets ≥ 100 x10^3 /μL; Hemoglobin > 9.0 g/dL; INR < 1.5 and PTT < 1.5 x ULN in absence of anticoagulation or therapeutic levels in presence of anticoagulation
Kidney function
Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 50 mL/min
Liver function
AST/ALT ≤ 2.5 x ULN (or < 5x ULN in patients with liver metastases); Total Bilirubin ≤ 1.5 x ULN (except Gilbert Syndrome < 3.0 mg/dL); Albumin ≥ 3.0 g/dL; CPK ≤ 2.5 x ULN
Cardiac function
Baseline QTc interval < 460 ms for women and ≤450 ms for men (Frederica's formula); LVEF >50% by ECHO or MUGA
Screening laboratory values must meet the following criteria: ... (see full text for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06007924 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MEK 1/2 inhibitor, inhibitor that targets Class II/Class III BRAF alterations, FAK inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
Does this trial require HRAS?
Yes, HRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages